10.6084/M9.FIGSHARE.19904814.V1
Xiaoxue Tian
Xiaoxue
Tian
Shufen Zheng
Shufen
Zheng
Jing Wang
Jing
Wang
Meiling Yu
Meiling
Yu
Zhuoheng Lin
Zhuoheng
Lin
Min Qin
Min
Qin
Yuanyuan Wu
Yuanyuan
Wu
Shiyu Chen
Shiyu
Chen
Shilong Zhong
Shilong
Zhong
Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review
<p>Although cardiac disorder-related adverse events (AEs) have been reported in patients treated with aryl hydrocarbon receptor (AHR) agonists, their safety profiles remain unknown. Here, we identified significant cardiac disorders associated with AHR agonists and further evaluated their relevance.</p> <p>Database queries were performed using OpenVigil 2.1 and AEs voluntarily submitted to Food and Drug Administration Adverse Event Reporting System (FAERS) between 2004 and 2020 were included. This study based on the Medical Dictionary for Regulatory Activities and the standardized MedDRA Queries to define the preferred terms, and we used reporting odd ratio to detect signals.</p> <p>In the FAERS database, 14,078 cardiac disorder-related AEs were identified in patients receiving AHR agonists. Among all AHR agonists, the number of cardiac disorder-related PTs with positive signals for AHR agonists was 93. Peripheral swelling (n = 1572) and atrial fibrillation (n = 1277) were the most reported cardiac disorder-related AEs among AHR agonists in disproportionately reported PTs. Moreover, several AHR agonists were highly associated with tachyarrhythmia.</p> <p>By mining the FAERS database, we provided more information on the association between AHR agonist use and cardiac disorder-related AEs.</p>
Biochemistry
Medicine
Cell Biology
Genetics
Molecular Biology
Physiology
Pharmacology
Biotechnology
Sociology
Immunology
Biological Sciences not elsewhere classified
Cancer
Science Policy
Taylor & Francis
2022
2022-05-27
2024-03-01
Journal contribution
225020 Bytes
10.6084/m9.figshare.19904814
10.1080/14740338.2022.2078301
CC BY 4.0